Vertex Pharmaceuticals (VRTX) Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals has reported Operating Expenses for 18 years, with the latest figure at $1.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 13.61% year-over-year to $1.8 billion; the trailing twelve-month figure through Mar 2026 stood at $7.5 billion (down 36.36% YoY), and the FY2025 full-year result was $7.8 billion, down 30.44% from the prior year.
• Operating Expenses for Q1 2026 stood at $1.8 billion, down from $2.0 billion in the prior quarter.
• The five-year high for Operating Expenses was $6.2 billion in Q2 2024, with the low at $1.1 billion in Q1 2022.
• Average Operating Expenses over 5 years is $1.9 billion, with a median of $1.6 billion recorded in 2023.
• Year-over-year, Operating Expenses surged 319.98% in 2024 and plunged 70.56% in 2025.
• Tracing VRTX's Operating Expenses over 5 years: stood at $1.3 billion in 2022, then gained by 20.49% to $1.5 billion in 2023, then rose by 23.33% to $1.9 billion in 2024, then increased by 5.2% to $2.0 billion in 2025, then declined by 6.82% to $1.8 billion in 2026.
• The last three Operating Expenses figures came in at $1.8 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.

Peer Comparison